Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder.
Attention-deficit hyperactivity disorder (ADHD) is a very common condition in children and often extends into the adult years. Drugs such as methylphenidate, amphetamines and atomoxetine are frequently prescribed as part of management. The use of these drugs has been increasing and significant clinical benefit is achieved but safety has been questioned. In this review, the cardiovascular safety of these drugs is examined with regard to effects on blood pressure (BP), heart rate (HR), ECG parameters and the risk of sudden death. Methylphenidate appears to cause minor increases in BP and HR. There are no strong data to suggest that methylphenidate increases the corrected QT interval (QTc). Amphetamines appear to cause minor increases in HR and BP over the long term. There is growing evidence to suggest that amphetamines do not cause statistically or clinically significant increases in QTc. Sudden death remains an extremely rare event and there is no clear evidence to attribute this to methylphenidate. Some data even suggest that the risk of sudden death in treated children may be less common than in the background population. Limited data suggest that atomoxetine may increase BP and HR in the short term; in the long term it appears to increase BP. The effects of atomoxetine on QTc remain uncertain. Use of this drug does not appear to be associated with sudden death. Because the current evidence is based on research that has not been specifically designed to investigate the cardiovascular effects of these drugs it is difficult to draw firm conclusions, and further work is required specifically to address these questions.
Stiefel
Gary
G
St Mary's Hospital, London, UK.
Besag
Frank M C
FM
D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000662:Amphetamines / Q000009:adverse effects* / Q000627:therapeutic use; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy; D001794:Blood Pressure / Q000187:drug effects; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000627:therapeutic use; D004562:Electrocardiography; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008774:Methylphenidate / Q000009:adverse effects* / Q000627:therapeutic use; D011437:Propylamines / Q000009:adverse effects* / Q000627:therapeutic use
D018759:Adrenergic Uptake Inhibitors; D000662:Amphetamines; D000697:Central Nervous System Stimulants; D011437:Propylamines; D008774:Methylphenidate; D000069445:Atomoxetine Hydrochloride
J Am Acad Child Adolesc Psychiatry. 2005 Jun;44(6):510
15908831
Clin Ther. 2007 Mar;29(3):450-63
17577466
J Am Acad Child Adolesc Psychiatry. 2006 Aug;45(8):919-927
16865034
Clin Toxicol (Phila). 2006;44(3):243-7
16749540
J Child Adolesc Psychopharmacol. 2001 Fall;11(3):251-65
11642475
Arch Pediatr Adolesc Med. 2006 Jan;160(1):82-90
16389216
Pediatrics. 2002 Mar;109(3):E39
11875167
Pediatrics. 2006 Sep;118(3):1215-9
16951018
J Child Adolesc Psychopharmacol. 2006 Jun;16(3):351-6
16768642
Arch Dis Child. 2006 Dec;91(12):1023-4
17119076
N Engl J Med. 1986 Dec 4;315(23):1485
3785299
J Clin Psychiatry. 2003 Oct;64(10):1163-9
14658963
Pediatrics. 2002 Aug;110(2 Pt 1):258-66
12165576
N Engl J Med. 2006 Apr 6;354(14):1445-8
16549404
Am J Psychiatry. 2009 Sep;166(9):992-1001
19528194
Pediatrics. 2008 Aug;122(2):451-3
18676566
Pediatrics. 2001 Oct;108(4):883-92
11581440
N Engl J Med. 2006 May 25;354(21):2296-8; author reply 2296-8
16729375
J Pediatr. 2006 Jul;149(1):112-9
16860138
Arch Gen Psychiatry. 1999 Apr;56(4):330-6
10197827
Am J Psychiatry. 2004 Apr;161(4):757
15056530
Int Clin Psychopharmacol. 1988 Apr;3(2):167-81
3294285
Pediatr Nephrol. 2006 Jan;21(1):92-5
16254730
Drug Saf. 2003;26(10):729-40
12862507
Clin Psychol Rev. 2002 Nov;22(8):1107-31
12436807
Neurology. 2005 Dec 27;65(12):1941-9
16380617
J Dev Behav Pediatr. 2008 Aug;29(4):335
18698199
J Am Acad Child Adolesc Psychiatry. 2005 Oct;44(10):1015-23
16175106
J Am Acad Child Adolesc Psychiatry. 2003 Oct;42(10):1203-11
14560170
Pediatrics. 2007 Jan;119(1):154-5
17200281
J Pediatr. 2005 Sep;147(3):348-54
16182674
Pediatrics. 1987 Jan;79(1):1-25
3797155
J Clin Pharmacol. 2005 Jul;45(7):851-5
15951476
CNS Drugs. 2008;22(3):213-37
18278977
Drug Saf. 2009;32(11):1089-96
19810780
Circulation. 2008 May 6;117(18):2407-23
18427125
J Am Acad Child Adolesc Psychiatry. 2007 Feb;46(2):242-51
17242628
J Child Adolesc Psychopharmacol. 1992 Winter;2(4):279-90
19630610
Eur Child Adolesc Psychiatry. 2006 Dec;15(8):450-9
16791541
J Am Acad Child Adolesc Psychiatry. 2001 May;40(5):525-9
11349696
Hypertension. 2007 Jul;50(1):47-53
17515448
J Child Adolesc Psychopharmacol. 2005 Aug;15(4):637-54
16190795
Adv Ther. 2007 Jan-Feb;24(1):182-8
17526476
Biol Psychiatry. 2007 Mar 1;61(5):706-12
16899230
J Am Acad Child Adolesc Psychiatry. 2002 Jul;41(7):776-84
12108801
Eur Heart J. 2001 Apr;22(8):702-11
11286528
CNS Spectr. 2008 Jul;13(7):614-20
18622366
J Child Adolesc Psychopharmacol. 2006 Aug;16(4):441-55
16958569
Drug Saf. 2009;32(11):1097-100
19810781
Child Adolesc Psychiatry Ment Health. 2007 Sep 28;1(1):11
17903242
J Clin Psychiatry. 2002 Dec;63(12):1140-7
12523874
J Clin Psychopharmacol. 2004 Feb;24(1):36-41
14709945
J Child Adolesc Psychopharmacol. 2007 Feb;17(1):63-73
17343554
Clin Ther. 2006 Feb;28(2):266-79
16678648
Pediatrics. 2003 Nov;112(5):e404
14595084
J Am Acad Child Adolesc Psychiatry. 2009 Feb;48(2):176-85
20040824
J Am Acad Child Adolesc Psychiatry. 2007 Nov;46(11):1445-53
18049294
Pediatrics. 2001 Nov;108(5):E83
11694667